Seeks enhancements to stockholder communication, investment community engagement and corporate governance Raises concerns regarding the material undervaluation of the company’s shares and dramatic underperformance relative to public comparables FTAI Aviation and AerCap Believes issues plaguing company are readily addressable through straightforward remedies that would benefit all stockholders Issues letter publicly after efforts at private engagement failed PORTSMOUTH, N.H., Jan. 06, 2026 (GLOBE NEWSWIRE) - ...

Core Viewpoint - General Motors is on track to become the top U.S.-traded automaker stock of 2025, experiencing its best performance since emerging from bankruptcy in 2009 [1] Group 1: Stock Performance - GM stock has increased over 55% to a record of more than $80 per share, surpassing last year's annual increase of 48.3% [2] - The stock has seen a nearly 13% increase this month, contributing to five consecutive months of gains [2] - GM's stock performance is notably better compared to competitors, with Tesla up 17%, Ford up 34%, and Stellantis down 15% [4] Group 2: Executive Insights - CEO Mary Barra has stated that GM's strong financial results, innovative technology, and customer experience will differentiate the company in a competitive market [3] - Barra has significantly reduced her stake in the company, selling or exercising options on approximately 1.8 million shares valued at over $73 million this year [3] - As of September, Barra still holds over 433,500 shares valued at more than $35 million, primarily from options and stock awards [3]

Core Viewpoint - Analysts believe Nvidia (NVDA) is significantly undervalued, with expectations of dramatic contraction in valuation multiples over the next few years as the company continues to convert [1] Group 1: Company Insights - Nvidia is positioned for significant growth, with analysts highlighting its undervaluation in the current market [1] - The company is expected to maintain a strong focus on converting its business model, which may lead to improved financial performance [1] Group 2: Analyst Background - The analyst has a decade of experience at a Big 4 audit firm, specializing in banking, mining, and energy sectors, providing a strong foundation in finance and strategy [1] - Currently, the analyst serves as the Head of Finance for a leading retail real estate operator, overseeing complex financial operations and strategy [1] - The analyst has been an active investor in the U.S. stock market for 13 years, focusing on a balanced investment approach that includes value stocks and growth opportunities [1]

Core Viewpoint - Innovative Aerosystems (ISSC) is experiencing significant growth and has a new price target of $20 set by Craig-Hallum, indicating strong confidence in its future performance [1][6]. Financial Performance - ISSC reported a remarkable 78.6% increase in revenue for fiscal year 2025, with a GAAP EPS of $0.39, contributing to a total return of 72% over the past month [2][6]. - The stock currently trades at a trailing P/E ratio of 16.66x, which is attractive compared to sector medians, and the PEG ratio is well below sector averages, suggesting potential undervaluation relative to growth [3][6]. Stock Performance - The current stock price of ISSC is $16.11, reflecting a 12.09% increase with a change of $1.74, and it has fluctuated between $14.50 and $16.20 today [4]. - Over the past year, the stock has reached a high of $20 and a low of $5.30, with a market capitalization of approximately $284.1 million [4]. Market Activity - The trading volume for ISSC today is 391,146 shares, indicating active investor interest, and the new price target suggests potential for further growth [5].

Core Thesis - Celsius Holdings, Inc. is experiencing significant growth, with a notable 110% revenue increase in Q3, reaching $721 million in sales, and a U.S. market share of 12.1% [2][3] Financial Performance - The company reported a gross margin of 53.4%, with adjusted EBITDA rising by 181% and net income increasing by 223% to $165.7 million, attributed to disciplined marketing and administrative spending [3] - Despite strong financials, the stock price fell by 27% post-earnings due to market sentiment shifts and concerns over acquisition integration [4] Strategic Partnerships and Expansion - Celsius's partnership with PepsiCo has significantly boosted distribution, leading to a 109% increase in North American revenue and a 126% increase in international revenue as the company expands into markets like the U.K., Ireland, France, Australia, and New Zealand [3] Balance Sheet Strength - With $865 million in cash and near-zero long-term debt, Celsius is positioned as a strong player in the consumer beverages sector, ready for aggressive expansion [4] Market Sentiment and Valuation - Analysts have adjusted Q4 profit assumptions downward, raising concerns about whether Celsius can maintain its high-growth status or if it is overvalued [5] - Current valuation models suggest that shares are undervalued, with intrinsic value estimated between $46 and $65, indicating a critical inflection point for the company [5] Historical Context - Previous bullish theses highlighted resilient demand and strong brand momentum, with a 5.13% stock price appreciation since earlier coverage, supporting the long-term growth narrative [6]

Core Viewpoint - Galloway Capital Partners has acquired a 3.15% stake in PodcastOne, Inc., indicating a belief that the company's shares are significantly undervalued compared to its revenues and intrinsic value [1] Company Analysis - Galloway Capital Partners' Chief Investment Officer, Bruce Galloway, highlighted that PodcastOne's shares are trading at a material discount [1] - The analysis suggests that PodcastOne's valuation is not reflective of its potential, as evidenced by recent acquisitions in the sector reaching valuations of up to 10 times revenues [1]

Group 1 - The article does not provide any relevant content regarding company or industry insights [1]

Core Insights - The article provides a market analysis focusing on Eli Lilly and Company, Novo Nordisk A/S, and Akero Therapeutics Inc, highlighting their performance and market trends [1] Company Analysis - Eli Lilly and Company has shown significant growth in its diabetes and obesity treatment segments, contributing to its overall revenue increase [1] - Novo Nordisk A/S continues to dominate the diabetes care market, with strong sales figures and a robust pipeline of new products [1] - Akero Therapeutics Inc is emerging in the liver disease treatment space, with promising clinical trial results that could enhance its market position [1] Industry Trends - The diabetes and obesity treatment market is experiencing rapid growth, driven by increasing prevalence rates and rising healthcare expenditures [1] - There is a growing focus on innovative therapies and personalized medicine within the pharmaceutical industry, particularly in the treatment of chronic diseases [1] - Regulatory changes and advancements in technology are shaping the competitive landscape, providing both opportunities and challenges for companies in the sector [1]

Core Insights - Heartland Advisors reported a strong performance for small-cap stocks in Q3 2025, with the Russell 2000® Index increasing by 12.39%, outperforming the S&P 500 Index's 8.12% rise [1] - The Heartland Value Plus Fund achieved an 8.51% return in Q3 2025, lagging behind the Russell 2000® Value Index, which gained 12.60% [1] Company Highlights - PHINIA Inc. (NYSE:PHIN), a spin-off from BorgWarner, focuses on developing integrated components and systems for vehicles and industrial applications, aiming to enhance performance and reduce emissions [2] - PHINIA Inc. experienced a one-month return of -9.93%, but its shares increased by 13.30% over the past 52 weeks, closing at $51.78 on October 10, 2025, with a market capitalization of $2.014 billion [2] Investment Strategy - The Heartland Value Plus Fund emphasized that stock selection is most effective when management actions confirm improving fundamentals, such as share buybacks, insider buying, and growing dividends [3] - Currently, approximately one-third of the fund's holdings have insider buying, 84% of the companies are engaged in active buybacks, and 61% have raised dividends in the past year [3]

Core Insights - Volaris (NYSE: VLRS) was identified as deeply undervalued in January 2025, yet its share price has decreased by approximately 50% since then [1]. Company Performance - The share price decline of Volaris is notable, indicating potential challenges in the company's market performance despite previous assessments of undervaluation [1].